pharma operations – Page 33

Material specification drift during scale-up – documentation gaps regulators question

Investigating Material Specification Drift During Scale-Up for Enhanced Compliance Material specification drift during scale-up poses significant challenges for pharmaceutical manufacturing organizations. When the specifications of raw materials shift unintentionally during…

Patch management weaknesses during system upgrades – data integrity risk and remediation

Identifying and Addressing Patch Management Weaknesses During System Upgrades in Pharma In today’s increasingly regulated pharmaceutical landscape, effective management of IT systems is critical to safeguarding data integrity and ensuring…

Packaging compatibility risk during inspection readiness – regulatory risk analysis and mitigation

Assessing Packaging Compatibility Risks During Inspection Readiness and Mitigating Regulatory Issues Pharmaceutical packaging plays a crucial role in maintaining product integrity and compliance with regulatory standards. However, risks associated with…

Interface validation gaps during data integrity review – FDA/EMA expectations for computerized systems

“`html Addressing Gaps in Interface Validation during Data Integrity Review: A Structured Investigation In the fast-paced world of pharmaceutical manufacturing, ensuring data integrity is paramount. Interface validation gaps can lead…

Extractables and leachables concern during supplier change – inspection evidence expectations

Investigating Extractables and Leachables Concerns During Supplier Changes: Evidence Expectations Extractables and leachables (E&L) represent a critical concern during the supplier change process in pharmaceutical manufacturing. These substances can potentially…

CSV not aligned to actual use during system operation – inspection evidence pack preparation

Examining the Misalignment of CSV with Operational Practices in Pharmaceutical Systems In the pharmaceutical industry, ensuring that computer system validation (CSV) aligns with actual operational use is paramount for maintaining…

Artwork change error during supplier change – documentation gaps regulators question

Analyzing Artwork Change Errors During Supplier Transitions and Addressing Documentation Gaps Comprehensively In the dynamic environment of pharmaceutical operations, the accuracy and compliance of artwork changes are critical, particularly during…

Patch management weaknesses during validation lifecycle – FDA/EMA expectations for computerized systems

Understanding Patch Management Weaknesses in the Validation Lifecycle: FDA and EMA Considerations In a highly regulated industry like pharmaceuticals, ensuring that computerized systems remain compliant throughout their lifecycle is paramount.…

Packaging compatibility risk during scale-up – CAPA and control strategy

“`html Understanding and Managing Packaging Compatibility Risks During Scale-Up In pharmaceutical manufacturing, the scale-up phase can introduce various risks, particularly regarding packaging compatibility. As processes shift from development to larger…

Tag: pharma operations